University College of London collaboration: DBDNA™ for gene therapy
Touchlight has entered into collaboration with Professor Simon Waddington’s group at the Institute for Women’s Health at UCL. The collaboration aims to investigate the potential to generate conventional gene therapy viral vectors (specifically lentivirus and adeno-associated virus) using doggybones™ in a triple transfection system
- ENDS -
Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as “doggybone DNA” or dbDNA™.
dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.
Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.
Issued for and on behalf of Touchlight by Instinctif Partners.
For more information please contact:
|Jonny Ohlson, CEO||Tim Watson|
|Robin Bodicoat, Head of Marketing||Agnes Stephens|
|E: email@example.com||E: firstname.lastname@example.org|
|T: +44 20 8481 9200||T: +44 20 7457 2020|